APP and Alzheimer disease: The result of our study in an AD mouse model overexpressing human amyloid precursor protein containing the Swedish and London mutation and human QC (hAPPsl×hQC) indicates an additive effect of both treatment strategies which might open up new avenues for an AD treatment by combining two disease-modifying Aβ-directed therapies in a practical clinical setting in future.